Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RX-5902 |
Synonyms | |
Therapy Description |
Supinoxin (RX-5902) binds to and inhibits Ddx5, which in turn inhibits beta-catenin signaling, results in down-regulation of gene expression and tumor cell growth inhibition (PMID: 25649741, PMID: 31488700). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RX-5902 | Supinoxin | CTNNB1 Inhibitor 27 | Supinoxin (RX-5902) binds to and inhibits Ddx5, which in turn inhibits beta-catenin signaling, results in down-regulation of gene expression and tumor cell growth inhibition (PMID: 25649741, PMID: 31488700). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02003092 | Phase I | RX-5902 | RX-5902 Treatment of Subjects With Solid Tumors | Terminated | USA | 0 |